Skip to content
NEWSnet Orlando
    • Homepage
Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis

Category: Trending

Posted Date:

June 7, 2026
  • Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis

    Zealand Pharma
    June 7, 2026
  • Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity

    Boehringer Ingelheim Limited
    June 7, 2026
  • Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

    Sciwind Biosciences Co., Ltd.
    June 7, 2026
  • Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

    AMERICAN DIABETES ASSOCIATION
    June 7, 2026
  • Investors Worldwide Are Discovering New Opportunities In Lithium, Rare Earth Minerals, and EV Technology

    Elektros, Inc.
    June 7, 2026
  • Billionaires, Millionaires, Microcap and Penny Stock Investors: The Global Race for Lithium, Rare Earth Minerals and EV Technology Is Accelerating

    Elektros, Inc.
    June 7, 2026
  • Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

    Antag Therapeutics
    June 7, 2026
Prev
1 … 1,448 1,449 1,450